
# PCSK9 INHIBITORS AND SELECT LIPOTROPICS PRIOR AUTHORIZATION REQUEST FORM



Today's Da	ate			
/		/		

## Note: This form must be completed by the prescribing provider.

## \*\*All sections must be completed or the request will be returned\*\*

Patient's Medicaid #	Date of Birth
Patient's Name	Prescriber's Name
Prescriber's IN License #	Specialty
Prescriber's NPI #	Prescriber's Signature
Return Fax #	Return Phone #         _         _         _         _
Check box if requesting retro-active PA	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

Requested Medication	Strength	Quantity	Dosage Regimen

PA R	equirements for Evkeeza (evinacumab-dgnb):
1.	Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) 🗌 Yes 🗌 No
2.	Medication prescribed by, or in consultation with, a cardiologist or endocrinologist $\ \square$ Yes $\ \square$ No
3.	Select one of the following:
	$\Box$ Member is 7 years of age or older and less than 10 years of age and one of the following:
	<ul> <li>Member has trial and failure history of at least 90 days of therapy with rosuvastatin 20 mg</li> <li>Yes No</li> <li>Provider has submitted documentation of intolerance/contraindication to rosuvastatin</li> <li>Yes No</li> </ul>
	$\Box$ Member is 10 years of age or older and less than 18 years of age and one of the following:
	i. Member has trial and failure history with Repatha (evolocumab)   Yes   No Drug/dose/date(s):
	ii. Member has trial and failure history of at least 90 days of high dose rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy concurrently with ezetimibe (or documented intolerance/contraindication to statins/ezetimibe) AND provider has submitted medical justification for use of Evkeeza (evinacumab-dgnb) over Repatha (evolocumab)

	<ul> <li>Member is 18 years of age or older and one of the following:</li> <li>Member has trial and failure history with Praluent (alirocumab) OR Repatha (evolocumab)</li> <li>Yes No</li> <li>Drug/dose/date(s):</li> </ul>
	<ul> <li>Member has trial and failure history of at least 90 days of high dose rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy concurrently with ezetimibe (or documented intolerance/contraindication to statins/ezetimibe) AND provider has submitted medical justification for use of Evkeeza (evinacumab-dgnb) over Praluent (alirocumab) and Repatha (evolocumab)   Yes   No Drug/dose/date(s):</li> </ul>
4.	Select one of the following: <ul> <li>Member will utilize maximally tolerated statin therapy with or without ezetimibe concurrently with Evkeeza (for those 7 years of age and older)</li> </ul>
5.	<ul> <li>Provider has submitted documented intolerance to statin and/or ezetimibe therapy or medical rationale against use of statin or ezetimibe therapy</li> <li>Requested dose is 15 mg/kg every 4 weeks or less</li> <li>Yes</li> <li>No</li> </ul>
0.	Member weight: LB/ KG (circle one)
PA Re	equirements for Juxtapid (lomitapide mesylate):
1.	Member is enrolled in the Juxtapid/lomitapide REMS program and prescriber is monitoring in accordance with REMS requirements $\Box$ Yes $\Box$ No
2.	Member is 18 years of age or older $\Box$ Yes $\Box$ No
3.	Medication prescribed by, or in consultation with, a cardiologist or endocrinologist $\ \square$ Yes $\ \square$ No
4.	Select one of the following:
	Member has trial and failure history of Praluent (alirocumab) or Repatha (evolocumab): Drug/dose/date(s):
	<ul> <li>Member has trial and failure history of at least 90 days of high dose rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy concurrently with ezetimibe (or documented intolerance/contraindication to statins/ezetimibe) AND provider has submitted medical justification for use of Juxtapid (lomitapide mesylate) over Praluent (alirocumab) and Repatha (evolocumab):</li> <li>Drug/dose/date(s):</li></ul>
5.	For those of childbearing potential, documentation of a negative pregnancy test obtained in the past 30 days is attached and prescriber has counseled member on risks associated with conceiving while utilizing Juxtapid and appropriate methods of contraception  Yes No Prescriber Name and Signature:
6.	Select one of the following:
	Member will utilize maximally tolerated statin therapy with or without ezetimibe concurrently with Juxtapid
	Provider has submitted documented intolerance to statin and/or ezetimibe therapy or medical rationale against use of statin or ezetimibe therapy
7.	Requested dose is 60 mg/day or less 🗌 Yes 🗌 No

PA Re	equirements for Leqvio (inclisiran):
1.	Select one of the following:
	Member has a diagnosis of primary hyperlipidemia with clinical atherosclerotic cardiovascular disease (ASCVD) or is at increased risk for ASCVD with a baseline LDL-C level of ≥55 mg/dL (documentation required)
	Member has diagnosis of heterozygous familial hypercholesterolemia (HeFH) with a baseline LDL-Clevel of ≥70 mg/dL (documentation required)
2.	Member is 18 years of age or older $\Box$ Yes $\Box$ No
3.	Prescribed by, or in consultation with, a cardiologist or endocrinologist $\ \square$ Yes $\ \square$ No
4.	Select one of the following:
	Member has trial and failure history of Praluent (alirocumab) or Repatha (evolocumab)
	Drug/dose/date(s):
	Member has trial and failure history of at least 90 days of high dose rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy concurrently with ezetimibe (or documented intolerance/contraindication to statins/ezetimibe) AND provider has submitted medical justification for use of Leqvio (inclisiran) over Praluent (alirocumab) and Repatha (evolocumab)
	Drug/dose/date(s):
5.	Select one of the following: <ul> <li>Member will utilize maximally tolerated statin therapy with or without ezetimibe concurrently with Leqvio</li> </ul>
	Provider has submitted documented intolerance to statin and/or ezetimibe therapy or medical rationale against use of statin or ezetimibe therapy
6.	Select one of the following:
	Member is initiating therapy and requested dose does not exceed 284 mg every 3 months
	$\Box$ Member is established on therapy and requested dose does not exceed 284 mg every 6 months
PA Re	equirements for Niacin ER
1.	Diagnosis of severe hypertriglyceridemia (baseline triglycerides ≥500 mg/dL) □ Yes □ No
	If Yes, then select one of the following: <ul> <li>Member is on concurrent therapy with all of the following for at least 90 days: omega-3 fatty acid (omega-3-acid ethyl esters or icosapent ethyl), fibric acid derivative, statin therapy</li> </ul>

- Drug/dose/date(s): \_
- Member has a documented intolerance of omega-3 fatty acid, fibric acid derivative, AND statin therapy OR medical justification for use of Niacin ER over omega-3 fatty acid, fibric acid derivative, AND statin therapy

Please explain: \_\_\_\_

2. Member is 17 years of age or older  $\Box$  Yes  $\Box$  No

# PA Requirements for Praluent (alirocumab):

•	nis for Praident (anrocumab).
1. Select one	of the following:
	Member has a diagnosis of clinical ASCVD, is at Very High Risk requiring therapy for secondary prevention, AND has persistently elevated LDL-C (≥55 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy*
	Member has a diagnosis of clinical ASCVD, is NOT at Very High Risk requiring therapy for secondary prevention, AND has persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy WITH ezetimibe or has documented intolerance of rosuvastatin and atorvastatin and/or ezetimibe OR medical rationale against the use of statin therapy and/or ezetimibe therapy
	Member has a diagnosis of clinical ASCVD, with a baseline LDL-C ≥190 mg/dL, not due to secondary causes, without clinical or genetic diagnosis of familial hypercholesterolemia, requiring therapy for secondary prevention AND has persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy*
	Member has a diagnosis of clinical ASCVD, is at Very High Risk with a baseline LDL-C $\geq$ 190 mg/dL not due to secondary causes, a diagnosis of familial hypercholesterolemia, requiring therapy for secondary prevention, AND has persistently elevated LDL-C ( $\geq$ 55 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy*
	Member has a diagnosis of primary hyperlipidemia, without clinical ASCVD, with a baseline LDL-C $\geq$ 190 mg/dL not due to secondary causes, with or without concomitant ASCVD risk factors, requiring therapy for primary prevention AND persistently elevated LDL-C ( $\geq$ 100 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy*
	Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) or heterozygous familial hypercholesterolemia (HeFH) AND persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy WITH ezetimibe or has documented intolerance of rosuvastatin and atorvastatin and/or ezetimibe OR medical rationale against the use of statin therapy and/or ezetimibe therapy
	mbers requiring >25% additional lowering of LDL-C ONLY (≤ 25% LDL-C lowering must gh intensity statin therapy WITH ezetimibe as first line)
Note: do	cumentation of any and all intolerances to statins and/or ezetimibe must be provided
-	of the above diagnoses that require medical justification for use of Praluent over statin zetimibe therapy, please provide justification here:
	less than 18 years of age □ Yes □ No
3. Select one □	of the following: Member will utilize maximally tolerated statin therapy with or without ezetimibe concurrently with Praluent
	Provider has submitted documented intolerance to statin and/or ezetimibe therapy or medical rationale against use of statin or ezetimibe therapy

<ol><li>Select or</li></ol>	ne of the following:
E	Requested dose is 75 mg every 2 weeks
[	Requested dose is 300 mg every 4 weeks
C	Requested dose is 150 mg every 2 weeks <b>AND the member has one of the following:</b>
	Diagnosis of homozygous familial hypercholesterolemia
	<ul> <li>Diagnosis of heterozygous familial hypercholesterolemia and member is undergoing LDL apheresis</li> </ul>
	<ul> <li>Member has not achieved clinically meaningful response after at least 4 weeks of dosing at 75 mg every 2 weeks or 300 mg every 4 weeks</li> </ul>

## PA Requirements for Praluent (alirocumab):

- 1. Select one of the following:
  - ☐ Member has a diagnosis of clinical ASCVD, is at Very High Risk requiring therapy for secondary prevention, AND has persistently elevated LDL-C (≥55 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy\*

☐ Member has a diagnosis of clinical ASCVD, is NOT at Very High Risk requiring therapy for secondary prevention, AND has persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy WITH ezetimibe or has documented intolerance of rosuvastatin and atorvastatin and/or ezetimibe OR medical rationale against the use of statin therapy and/or ezetimibe therapy

Member has a diagnosis of clinical ASCVD, with a baseline LDL-C ≥190 mg/dL, not due to secondary causes, without clinical or genetic diagnosis of familial hypercholesterolemia, requiring therapy for secondary prevention AND has persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy\*

- Member has a diagnosis of clinical ASCVD, is at Very High Risk with a baseline LDL-C ≥190 mg/dL not due to secondary causes, a diagnosis of familial hypercholesterolemia, requiring therapy for secondary prevention, AND has persistently elevated LDL-C (≥55 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy\*
- Member has a diagnosis of primary hyperlipidemia, without clinical ASCVD, with a baseline LDL-C ≥190 mg/dL not due to secondary causes, with or without concomitant ASCVD risk factors, requiring therapy for primary prevention AND persistently elevated LDL-C (≥100 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy or has documented intolerance of both rosuvastatin and atorvastatin OR medical rationale against the use of statin therapy\*

☐ Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) or heterozygous familial hypercholesterolemia (HeFH) AND persistently elevated LDL-C (≥70 mg/dL) despite treatment with 90 days of therapy with high intensity rosuvastatin (20 mg/40 mg) or atorvastatin (40 mg/80 mg, if rosuvastatin intolerant) therapy WITH ezetimibe or has documented intolerance of rosuvastatin and atorvastatin and/or ezetimibe OR medical rationale against the use of statin therapy and/or ezetimibe therapy

\* For members requiring >25% additional lowering of LDL-C ONLY (≤ 25% LDL-C lowering must utilize high intensity statin therapy WITH ezetimibe as first line)

Note: documentation of any and all intolerances to statins and/or ezetimibe must be provided

	ezetimibe therapy, please provide justification here:
,	Select one of the following:
	Member is 18 years of age or older
	$\Box$ Member is 10 years of age or older and has a diagnosis of either HoFH or HeFH
5.	Select one of the following:
	Member will utilize maximally tolerated statin therapy with or without ezetimibe concurrentl with Repatha
	Provider has submitted documented intolerance to statin and/or ezetimibe therapy or medic rationale against use of statin or ezetimibe therapy
	Select one of the following:
	Requested dose is 140 mg every 2 weeks
	Requested dose is 420 mg once monthly
	$\Box$ Requested dose is 420 mg every 2 weeks <b>AND the member has one of the following:</b>
	Diagnosis of HoFH and has not achieved clinically meaningful response after at least weeks at 420mg once monthly dosing
	Member is receiving lipid apheresis

CONFIDENTIAL INFORMATION This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.